{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:13:01Z","timestamp":1784031181140,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s11102-024-01461-5","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T22:01:53Z","timestamp":1727733713000},"page":"468-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis"],"prefix":"10.1007","volume":"27","author":[{"given":"Turkan","family":"Aliyeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Meira","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Firdausa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"issue":"4","key":"1461_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667\u2013678. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"1461_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","volume":"107","author":"MR Gadelha","year":"2022","unstructured":"Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107(2):297\u2013308. https:\/\/doi.org\/10.1210\/clinem\/dgab726","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1461_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2024.101875","volume":"38","author":"SZ Bhat","year":"2024","unstructured":"Bhat SZ, Salvatori R (2024) Current role of pasireotide in the treatment of acromegaly. Rec Adv Treat Acromegaly 38(4):101875. https:\/\/doi.org\/10.1016\/j.beem.2024.101875","journal-title":"Rec Adv Treat Acromegaly"},{"issue":"1","key":"1461_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11102-018-0926-y","volume":"22","author":"F Gatto","year":"2019","unstructured":"Gatto F et al (2019) Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 22(1):89\u201399. https:\/\/doi.org\/10.1007\/s11102-018-0926-y","journal-title":"Pituitary"},{"issue":"5","key":"1461_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707\u2013716. https:\/\/doi.org\/10.1530\/eje.0.1460707","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1461_CR6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1210\/jc.2008-1919","volume":"94","author":"S Lesche","year":"2009","unstructured":"Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S (2009) Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94(2):654\u2013661. https:\/\/doi.org\/10.1210\/jc.2008-1919","journal-title":"J Clin Endocrinol Metab"},{"key":"1461_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081816","author":"J Amar\u00f9","year":"2021","unstructured":"Amar\u00f9 J et al (2021) Octreotide and pasireotide combination treatment in somatotroph tumor cells: predominant role of SST2 in mediating ligand effects. Cancers. https:\/\/doi.org\/10.3390\/cancers13081816","journal-title":"Cancers"},{"issue":"6","key":"1461_CR8","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1210\/jc.2017-00135","volume":"102","author":"F Gatto","year":"2017","unstructured":"Gatto F et al (2017) In vitro head-to-head comparison between octreotide and pasireotide in gh-secreting pituitary adenomas. J Clin Endocrinol Metab 102(6):2009\u20132018. https:\/\/doi.org\/10.1210\/jc.2017-00135","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1461_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1210\/jc.2018-01524","volume":"104","author":"A Muhammad","year":"2018","unstructured":"Muhammad A et al (2018) Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab 104(3):915\u2013924. https:\/\/doi.org\/10.1210\/jc.2018-01524","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1461_CR10","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/jc.2003-031344","volume":"89","author":"LJ Hofland","year":"2004","unstructured":"Hofland LJ et al (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577\u20131585. https:\/\/doi.org\/10.1210\/jc.2003-031344","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1461_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2265.2005.02322.x","volume":"63","author":"J van der Hoek","year":"2005","unstructured":"van der Hoek J et al (2005) The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 63(2):176\u2013184. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02322.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1461_CR12","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1210\/jc.2009-2272","volume":"95","author":"S Petersenn","year":"2010","unstructured":"Petersenn S et al (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95(6):2781\u20132789. https:\/\/doi.org\/10.1210\/jc.2009-2272","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1461_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1461_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"issue":"11","key":"1461_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1461_CR16","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2169\/internalmedicine.4663-20","volume":"60","author":"K Fukunaga","year":"2021","unstructured":"Fukunaga K et al (2021) Successful therapy using pasireotide long-acting release for Cushing\u2019s disease merged with biochemical acromegaly. Intern Med Tokyo Jpn 60(7):1047\u20131053. https:\/\/doi.org\/10.2169\/internalmedicine.4663-20","journal-title":"Intern Med Tokyo Jpn"},{"issue":"1","key":"1461_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12020-016-1182-4","volume":"55","author":"M Fleseriu","year":"2017","unstructured":"Fleseriu M, Rusch E, Geer EB, ACCESS Study Investigators (2017) Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine 55(1):247\u2013255. https:\/\/doi.org\/10.1007\/s12020-016-1182-4","journal-title":"Endocrine"},{"key":"1461_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov206.30","author":"J Silverstein","year":"2015","unstructured":"Silverstein J (2015) Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly. Neuro-Oncol. https:\/\/doi.org\/10.1093\/neuonc\/nov206.30","journal-title":"Neuro-Oncol"},{"issue":"1","key":"1461_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"Schmid HA et al (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53(1):210\u2013219. https:\/\/doi.org\/10.1007\/s12020-016-0895-8","journal-title":"Endocrine"},{"issue":"8","key":"1461_CR20","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446\u20133453. https:\/\/doi.org\/10.1210\/jc.2013-1771","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1461_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-022-03158-w","volume":"78","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S et al (2022) Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78(2):343\u2013353. https:\/\/doi.org\/10.1007\/s12020-022-03158-w","journal-title":"Endocrine"},{"key":"1461_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02186-1","author":"G Corica","year":"2023","unstructured":"Corica G et al (2023) Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02186-1","journal-title":"J Endocrinol Invest"},{"key":"1461_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"11","key":"1461_CR24","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1461_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"1461_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"7109","key":"1461_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, DaveySmith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"issue":"3","key":"1461_CR28","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1461_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1507\/endocrj.EJ16-0624","volume":"64","author":"S Tahara","year":"2017","unstructured":"Tahara S et al (2017) Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr J 64(7):735\u2013747. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0624","journal-title":"Endocr J"},{"issue":"2","key":"1461_CR30","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"Shimon I et al (2018) Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62(2):448\u2013455. https:\/\/doi.org\/10.1007\/s12020-018-1690-5","journal-title":"Endocrine"},{"issue":"10","key":"1461_CR31","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1530\/EC-19-0332","volume":"8","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Ferriere A, Vasiljevic A, Eimer S, Nunes M-L, Tabarin A (2019) Pasireotide-LAR in acromegaly patients treated with a combination therapy: A real-life study. Endocr Connect 8(10):1383\u20131394. https:\/\/doi.org\/10.1530\/EC-19-0332","journal-title":"Endocr Connect"},{"key":"1461_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00931","author":"M Gadelha","year":"2020","unstructured":"Gadelha M et al (2020) Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2019.00931","journal-title":"Front Endocrinol"},{"key":"1461_CR33","doi-asserted-by":"publisher","first-page":"A525","DOI":"10.1210\/jendso\/bvab048.1071","volume":"5","author":"M Stelmachowska-Banas","year":"2021","unstructured":"Stelmachowska-Banas M, Czajka-Oraniec IK, Tomasik A, Zgliczynski W (2021) Real-world experience with pasireotide lar in acromegaly resistant to first-generation somatostatin analogs: a single center 1-year observation. J Endocr Soc 5:A525\u2013A526. https:\/\/doi.org\/10.1210\/jendso\/bvab048.1071","journal-title":"J Endocr Soc"},{"issue":"3","key":"1461_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","volume":"18","author":"M Sheppard","year":"2015","unstructured":"Sheppard M et al (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicentre, Phase III study. Pituitary 18(3):385\u2013394. https:\/\/doi.org\/10.1007\/s11102-014-0585-6","journal-title":"Pituitary"},{"key":"1461_CR35","doi-asserted-by":"publisher","unstructured":"Gadelha M, Bronstein M, Brue T, et al (2017) Long-acting pasireotide provides clinical benefit in patients with acromegaly: results from a 30-month analysis of the phase 3 Paola Study. ENDO 2017. Sun432 abstract, Endocr Rev 38(Supplement 1):i1\u2013i1431. https:\/\/doi.org\/10.1093\/edrv\/38.supp.1","DOI":"10.1093\/edrv\/38.supp.1"},{"issue":"2","key":"1461_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","volume":"74","author":"A Akirov","year":"2021","unstructured":"Akirov A et al (2021) Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine 74(2):396\u2013403. https:\/\/doi.org\/10.1007\/s12020-021-02782-2","journal-title":"Endocrine"},{"issue":"7","key":"1461_CR37","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1210\/jc.2004-2466","volume":"90","author":"S Melmed","year":"2005","unstructured":"Melmed S et al (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90(7):4405\u20134410. https:\/\/doi.org\/10.1210\/jc.2004-2466","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1461_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11102-015-0677-y","volume":"19","author":"A Colao","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R (2016) The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 19(2):210\u2013221. https:\/\/doi.org\/10.1007\/s11102-015-0677-y","journal-title":"Pituitary"},{"issue":"2","key":"1461_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247\u2013271. https:\/\/doi.org\/10.1210\/er.2010-0002","journal-title":"Endocr Rev"},{"key":"1461_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.935759","volume":"13","author":"A Mondin","year":"2022","unstructured":"Mondin A et al (2022) Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis. Front Endocrinol 13:935759. https:\/\/doi.org\/10.3389\/fendo.2022.935759","journal-title":"Front Endocrinol"},{"issue":"4","key":"1461_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/EC-19-0004","volume":"8","author":"AF Daly","year":"2019","unstructured":"Daly AF et al (2019) AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocr Connect 8(4):367\u2013377. https:\/\/doi.org\/10.1530\/EC-19-0004","journal-title":"Endocr Connect"},{"issue":"10","key":"1461_CR42","doi-asserted-by":"publisher","first-page":"EC-23-0155","DOI":"10.1530\/EC-23-0155","volume":"12","author":"NV Marques","year":"2023","unstructured":"Marques NV, Wildemberg LEA, Gadelha MR (2023) Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly. Endocr Connect 12(10):EC-23-0155. https:\/\/doi.org\/10.1530\/EC-23-0155","journal-title":"Endocr Connect"},{"issue":"6","key":"1461_CR43","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1210\/jc.2018-01979","volume":"104","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, Muhammad A, van der Lely AJ, Janssen JAMJL, Neggers SJCMM (2019) How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metab 104(6):1978\u20131988. https:\/\/doi.org\/10.1210\/jc.2018-01979","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1461_CR44","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL et al (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary 24(6):887\u2013903. https:\/\/doi.org\/10.1007\/s11102-021-01161-4","journal-title":"Pituitary"},{"issue":"8","key":"1461_CR45","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.clinthera.2014.06.006","volume":"36","author":"X Chen","year":"2014","unstructured":"Chen X et al (2014) Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. Clin Ther 36(8):1196\u20131210. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.006","journal-title":"Clin Ther"},{"issue":"1","key":"1461_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12020-018-1524-5","volume":"61","author":"A Albani","year":"2018","unstructured":"Albani A et al (2018) Pasireotide treatment reduces cardiometabolic risk in Cushing\u2019s disease patients: an Italian, multicenter study. Endocrine 61(1):118\u2013124. https:\/\/doi.org\/10.1007\/s12020-018-1524-5","journal-title":"Endocrine"},{"issue":"3","key":"1461_CR47","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1210\/clinem\/dgz054","volume":"105","author":"S Chiloiro","year":"2020","unstructured":"Chiloiro S et al (2020) Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J Clin Endocrinol Metab 105(3):e100\u2013e107. https:\/\/doi.org\/10.1210\/clinem\/dgz054","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01461-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01461-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01461-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T19:03:36Z","timestamp":1730747016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01461-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1461"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01461-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4790912\/v1","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"21 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report no relationships that could be construed as a conflict of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}]}}